Combination therapy with the 5-α reductase inhibitor finasteride ['Proscar'] plus the α1receptor blocker doxazosin ['Cardura'] is more effective in slowing the progression of benign prostatic hyperplasia (BPH) than treatment with either agent alone, according to results from the MTOPS*study presented at the 97th Annual Meeting of the American Urological Association (AUA) [Orlando, US; May 2002]. Significant improvements in all BPH symptoms evaluated, and reductions in the risk of disease progression, were observed in patients treated with the combination therapy, compared with placebo recipients. However, only finasteride monotherapy was shown to significantly reduce the risk of prostate cancer.